PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Bio-Modeling Systems

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bio-Modeling Systems Confirms its World's Leadership in Heuristic Systems Biology - BMSystems confirms its world's leadership in heuristic systems biology. Since its creation, the company generated new knowledge and innovations in the fields of cancer, psychiatric & cognitive disorders, neurodegenerative infectious diseases
Bio-Modeling Systems Confirms its World's Leadership in Heuristic Systems Biology

 

NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2010/10/22 - BMSystems confirms its world's leadership in heuristic systems biology. Since its creation, the company generated new knowledge and innovations in the fields of cancer, psychiatric & cognitive disorders, neurodegenerative infectious diseases.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bio-Modeling Systems confirms its world's leadership in heuristic systems biology. Since its creation in 2004, the company generated new knowledge and innovations in the fields of cancer, psychiatric & cognitive disorders, neurodegenerative and infectious diseases.
2011: 19th European Congress of Psychiatry: Vienna, Austria, 12-15 March 2011, organised by the European Psychiatric Association (EPA), the largest international association of psychiatrists in Europe. Dr. François IRIS is invited to present: "Methodology of Mapping in Integrative Molecular Biology associated to psychiatric and cognitive disorders".

Our last 3 years scientific contributions (public domain only):

1. 2010: Publication with Pherecydes-Pharma. Genetically Engineered Virulent Phage Banks in the Detection and Control of Emergent Pathogenic Bacteria published in Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science USA.

2. 2010: Molecular microbiology conference organized by the CNRS. BMSystems was invited to present its disruptive achievements in the field of bacteria/phages research.

3. 2010: BMSystems Invited to present at the 6th International Workshop on Computational Neuropsychiatry Systems Biology of Affective Disorders; Munich.

4. 2010: The Directorate-General (DG) of Research at The European Commission recognizes BMSystems' scientific excellence and innovative business model by inviting it to contribute its expertise to key decisional meetings. The workshop "From Systems Biology to Systems Medicine” report now available.

5. 2009: Launch of a spin-off by CEA Life Sciences based on a CEA-BMSystems co-patent in the field of psychiatric disorders treatments.

6. 2009: Prestigious Bio-IT World 2009 Best Practice Award for the in-vivo validation of the Creutzfeldt-Jakob disease model. The world's first in-vivo validation of a in-silico model of a complex human neurological disease. BMSystems was the only EU team rewarded in 2009.

7. 2008: BMSystems Co-published BioMarkers for Psychiatric Disorders with Dr. Chris Turck, Max Planck Institute of Psychiatry; Munich.

8. 2008-2010: Dr. François Iris, CSO of BMSystems co-leader of the Evaluation committee of the funding priorities in the “Medical Systems Biology- MedSys” program; German Federal ministry of Research; Berlin.

Being the first, and to date the only company that succeeded to create validated in-silico heuristic models of complex human pathologies and physiological processes, we offer to pharma companies the possibility to generate new & pertinent hypotheses, stop in time existing programs and launch lower risks, novel therapeutics programs without being obliged to change their existing R&D discovery processes.

Created in 2004, and profitable since 2006, we designed a unique heuristic systems biology business offer to provide all our partners and clients with a simplified results-oriented research paradigm that alleviates global R&D/business issues.
· Because we do not sell our technologies, but deliver their outputs in open formats, our clients are not dependent upon external proprietary technologies to maintain and update these new & pertinent hypotheses.
· Because clients' proprietary data protection is critical, we do not use their proprietary data to generate the first version of a CADI model, and we limit data transfers to experimentations results only during the CADI model validation phase.
If you are interested to learn more about our recent achievements and possible collaborations in the fields of neurodegenerative diseases, psychiatric and cognitive disorders, infectious diseases and cancer we shall happy to meet people of your company looking for such business proposals at Bio-Europe in Munich: November 14-17, 2010.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bio-Modeling Systems

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bio-Modeling Systems Confirms its World's Leadership in Heuristic Systems Biology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Manuel Gea - BMSystems.net 
+33(0)6 83 06 12 72 manuel.gea[.]bmsystems.net
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio-Modeling Systems securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bio-Modeling Systems / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)